Abstract
Abstract not available.
Highlights
To assess Psoriasis Area and Severity Index (PASI) at the time of, and following, dose adjustment in the open-label extension period of three phase 3 clinical trials of certolizumab pegol in psoriasis
We report patterns of dose adjustment between Certolizumab pegol (CZP) 400 mg and 200 mg Q2W, and changes from baseline PASI, in phase 3 trials
Data were pooled from the CIMPASI-1 (NCT02326298), CIMPASI-2 (NCT02326272), and CIMPACT (NCT02346240) trials (Figure 1)
Summary
Plaque psoriasis (PSO) is an immune-mediated, inflammatory disease that affects 2−4% of adults.. Certolizumab pegol (CZP), an Fc-free, PEGylated anti-tumor necrosis factor biologic, has demonstrated efficacy and safety in moderate to severe PSO.. We report patterns of dose adjustment between CZP 400 mg and 200 mg Q2W, and changes from baseline PASI, in phase 3 trials
Sign-in/Register to view highlights & summary 
Published Version (
Free)
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call